Feasibility of tomographic 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocaridal area at risk and the effect of treatment in acute myocardial infarction

R. J. Gibbons, M. S. Verani, T. Behrenbeck, P. A. Pellikka, M. K. O'Connor, J. J. Mahmarian, J. H. Chesebro, F. J. Wackers

Research output: Contribution to journalArticle

275 Scopus citations

Abstract

99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile (Tc-Sestamibi), a new myocardial perfusion radiopharmaceutical, was injected intravenously in 11 patients within 4 hours of the onset of acute myocardial infarction before treatment with intravenous tissue-type plasminogen activator and 6-14 days later. Five patients with acute myocardial infarction who did not receive intravenous thrombolytic therapy underwent a similar injection of radiopharmaceutical. The absence of redistribution of Tx-Sestamibi permitted imaging with single-photon emission computed tomography up to 6 hours after intravenous injection to assess the distribution of myocardial perfusion at the time of administration. The region of hypoperfused myocardium on the initial images varied widely from 9% to 68% of the left ventricle and was significantly greater in anterior than in inferior infarcts (p < 0.01). The region of hypoperfused myyocardium on the final images varied widely from 0% to 63% of the left ventricle and was also greater in anterior infarcts (p < 0.01). The final hypoperfused region correlated (r = -0.82) with the late resting ejection fraction and with the late regional wall motion score in the infarct segment for both anterior (r = -0.74) and inferior (r = -0.97) infarcts. There was a significant decrease (-13 ± 11%, p < 0.003) in the extent of hypoperfused myocardium between the initial and final studies in the patients who received thrombolytic therapy compared with an insignificant increase (4 ± 6%, p > 0.5) in the patients who did not receive thrombolytic therapy. Tomographic imaging with Tc-Sestamibi permits determination of the amount of hypoperfused myocardium 'at risk' in acute myocardial infarction. The change in myocardial perfusion determined by Tc-Sestamibi before and after therapy in acute myocardial infarction is a promising tool for assessing treatment.

Original languageEnglish (US)
Pages (from-to)1277-1286
Number of pages10
JournalCirculation
Volume80
Issue number5
DOIs
StatePublished - Jan 1 1989

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Feasibility of tomographic <sup>99m</sup>Tc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocaridal area at risk and the effect of treatment in acute myocardial infarction'. Together they form a unique fingerprint.

Cite this